COMBATING THE SARS-COV-2 OMICRON (BA.1) AND BA.2 WITH POTENT BISPECIFIC ANTIBODIES ENGINEERED FROM NON-OMICRON NEUTRALIZING ANTIBODIES

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Abstract The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs).In this study, we explored the possibility of combating the Omicron and BA.2 by constr

read more

A side-effect free method for identifying cancer drug targets

Abstract Identifying effective drug targets, with little or no side effects, remains an ever challenging task.A potential pitfall of failing to uncover the correct drug targets, due to side effect of pleiotropic genes, might lead the potential drugs to be illicit and withdrawn.Simplifying disease complexity, for the LEMON ZINGER investigation of th

read more